To ensure safety and trust in COVID-19 vaccination, Deloitte report urges rapid adoption of GS1 standards and barcodes

Global public health officials argue strongly for the “need to trace every vaccine dose”

As governments and businesses around the world face one of the most significant challenges in history – an unprecedented rapid mass development, distribution, and administration of Covid-19 vaccines – a new report issued by Deloitte points to universal adoption of global standards across the healthcare supply chain as an urgently needed solution to enable fast, efficient, and safe distribution. Global public health officials have reinforced those sentiments, with Tom Woods, Chairman of the Global Steering Committee for Quality Assurance of Health Products for the World Bank, calling for the adoption of common standards including barcode scanning, “the most important and under-discussed element in preventing vaccine distribution failures and ensuring traceability and patient safety in the COVID-19 vaccination campaign.”

The Deloitte study, “Securing Trust in the Global COVID-19 Supply Chain,” argues that, in addition to industry collaboration and transparent communication, “embracing GS1 standards adds an element of trust at all levels of the supply chain – a trust that ultimately extends to the patients themselves”. GS1 global standards enable pharmaceutical manufacturers, distributing companies and healthcare providers to follow protocols and safety measures critical to ensuring public trust and confidence, both in the vaccine itself and the ability to roll out vaccinations safely.

Barcodes carrying GS1 standards uniquely and securely identify medical products, including vaccines, from laboratories and clinical trials to point of administration. GS1 standards bring transparency and help to improve supply chain coordination, decreasing the risk of vaccine diversion, date expiration and fake vaccines proliferation. While the adoption of GS1 standards continues to expand in the healthcare field, they are not yet universally applied. The Deloitte study calls vaccine identification information (such as product identifier, lot number, and expiration date) “essential for healthcare providers to administer vaccines with confidence,” noting that, “the WHO recommends that all vaccines be identified with this data in a standardised barcode.” GAVI and UNICEF have also required the use of GS1 standards on the secondary packages of vaccines.

Miguel Lopera, President and CEO at GS1’s Global Office noted, “an unprecedented level of research, collaboration and investment has brought hope in the form of Covid-19 vaccines. The world now faces, however, an enormous distribution and administration challenge where global identification standards have a critical role to play. Countries around the world are implementing massive vaccination campaigns under enormous time pressure, all while the virus continues to kill thousands of people every day. Global standards can help to relieve the pressure on the healthcare industry and reduce the chances for error. GS1 stands ready to help all stakeholders succeed in this critical operation.”

Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte, added, “For vaccine developers, healthcare stakeholders and society at large, the level of transparency and public trust will determine Covid-19 vaccine acceptance and confidence. The continued adoption of global standards from organisations like GS1 are helping to instill that confidence in the Covid-19 vaccines.”

Today more than 70 countries have healthcare regulations or trading partner requirements for which industry uses GS1 standards. These countries rely on GS1 DataMatrix two-dimensional (2D) barcodes that can encode vaccine identification information to help reduce errors and enable traceability.

As some countries are experiencing tracking difficulties linking vaccines to patients at point of administration, the Deloitte report notes that “it is important to identify and label the vaccines capturing precisely which patient received which vaccine, and when.” Globally unique identification and GS1 barcoding can support that critical task.

Further information can be found on https://www.gs1.org/industries/healthcare/trust

ends

About GS1 Healthcare

GS1 Australia works in Healthcare to support adoption and implementation of interoperable GS1 standards within the Australian healthcare industry to enhance patient safety, and operational and supply chain efficiencies.

Our global community brings together healthcare stakeholders and experts to lead the successful development and implementation of global GS1 standards and guidelines. Evidence available from healthcare industry implementations shows that GS1 identification, data capture and data sharing standards deliver tangible benefit to all stakeholders - pharmaceutical and medical device manufacturers, wholesalers, distributors, group purchasing organisations, hospitals, pharmacies, logistics providers, solution providers, governmental and regulatory bodies, trade associations and most importantly patients and consumers of healthcare.

For more information about GS1 standards in Australian healthcare, visit the GS1 Australia website www.gs1au.org/healthcare and follow us on Twitter gs1au_health and LinkedIn gs1-australia.
GS1 media contact
Catherine Koetz
Industry Manager – Healthcare
GS1 Australia
D +61 3 9550 3403
M +61 4 3456 1501
E Catherine.Koetz@gs1au.org

Contacts
Wendy McWilliams
03 9803 2588
mailto: wendy@wmcpr.com.au